Invivyd (NASDAQ:IVVD – Get Free Report) issued its earnings results on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03, FiscalAI reports. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. The business had revenue of $15.45 million during the quarter, compared to the consensus estimate of $15.04 million.
Invivyd Stock Performance
NASDAQ IVVD opened at $0.58 on Monday. The stock has a fifty day simple moving average of $0.72 and a 200-day simple moving average of $1.09. The stock has a market cap of $171.58 million, a PE ratio of -1.76 and a beta of 1.20. Invivyd has a twelve month low of $0.53 and a twelve month high of $3.07.
Insider Transactions at Invivyd
In related news, insider Jill Andersen sold 30,706 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total value of $25,793.04. Following the sale, the insider directly owned 283,774 shares in the company, valued at approximately $238,370.16. The trade was a 9.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 103,024 shares of company stock valued at $86,540. 12.25% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on the stock. Weiss Ratings raised shares of Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research note on Monday, September 14th. HC Wainwright reiterated a “buy” rating on shares of Invivyd in a report on Tuesday, September 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Invivyd in a research note on Thursday, August 27th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $10.00.
Check Out Our Latest Analysis on IVVD
Invivyd Company Profile
Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.
Read More
- Five stocks we like better than Invivyd
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
